Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2

Conclusions Survival benefit with HDIL-2 is achieved in ~50 % patients and extends beyond those achieving objective responses.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research